Inhibitor of amyloid β42 (Aβ42) fibril assembly; reduces Aβ42-induced toxicity (EC50 = 2 μM).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 340.39. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.94 mL||14.69 mL||29.38 mL|
|5 mM||0.59 mL||2.94 mL||5.88 mL|
|10 mM||0.29 mL||1.47 mL||2.94 mL|
|50 mM||0.06 mL||0.29 mL||0.59 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Bohrmann et al (2000) Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J.Struct.Biol. 130 232 PMID: 10940228
If you know of a relevant reference for Ro 90-7501, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: inhibitors inhibits Aβ4 β42 beta42 fibril formation β-Amyloid beta-Amyloid b-amyloid Precursor Protein APP Secretase beta Peptides Ro90-7501 amyloidbeta amyloidb amyloidβ Amyloid Beta Peptides
Citations for Ro 90-7501
Citations are publications that use Tocris products.
Currently there are no citations for Ro 90-7501. Do you know of a great paper that uses Ro 90-7501 from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.